AstraZeneca has been named a sustainability leader within the Pharmaceuticals industry of the World Dow Jones Sustainability Index (DJSI World). The DJSI is the longest-running, global sustainability benchmark system and is based on an in-depth analysis of companies economic, social and environmental performance.
AstraZeneca’s overall score of 81 out of a possible 100 places the company only six points behind this year’s industry leader, Roche. AstraZeneca received the industry’s top score in the areas of Environmental Reporting, Labour Practice Indicators, and Health Outcome Contribution. AstraZeneca’s overall percentile increased 1 point to the 96th percentile. The average score in the pharmaceutical industry was 38. This marks the 17th time the company has been included in the Index.
Of 50 companies assessed from the Pharmaceuticals Industry Group, only 7 qualified for inclusion in the DJSI.
Maintaining a top three position in this prestigious index reflects the continued recognition for AstraZeneca’s sustainability efforts. Our improvements in the areas of health outcomes, environment and labour practices demonstrate how we are making great progress against our sustainability focus areas; health, environment and ethics. We are working towards long-term impact for people and the planet and there is more yet to come as we further embed sustainability into everything we do as a company.
I congratulate AstraZeneca for being included in the DJSI World Index. Companies that compete for a coveted place in the DJSI challenge themselves to continuously improve their sustainability practices and we are pleased to see that the number of companies that commit to achieving measurable positive impacts continues to rise.
The DJSI is a globally recognised independent benchmark that assesses – and ranks – the economic, environmental, and social performance of companies. It represents the gold standard for corporate sustainability and has become a key reference point for investors.
CONTACTS
Media Relations |
|
|
Karen Birmingham |
UK/Global |
+44 203 749 5634 |
Rob Skelding |
UK/Global |
+44 203 749 5821 |
Matt Kent |
UK/Global |
+44 203 749 5906 |
Gonzalo Viña |
UK/Global |
+44 203 749 5916 |
Jacob Lund |
Sweden |
+46 8 553 260 20 |
Michele Meixell |
US |
+1 302 885 2677 |
|
|
|
Investor Relations |
|
|
Thomas Kudsk Larsen |
+44 203 749 5712 |
|
Henry Wheeler |
Oncology |
+44 203 749 5797 |
Christer Gruvris |
Cardiovascular; Metabolism |
+44 203 749 5711 |
Nick Stone |
Respiratory; Renal |
+44 203 749 5716 |
Josie Afolabi |
Other |
+44 203 749 5631 |
Craig Marks |
Finance; Fixed Income; |
+44 7881 615 764 |
Jennifer Kretzmann |
Retail investors |
+44 203 749 5824 |
US toll free |
|
+1 866 381 7277 |
|
|
|